

	Particulars	Quarter ended		Year ended	
		31.03.2021		31.03.2021	
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
I	Revenue from Operations	7,586.28	7,177.17	4,236.83	25,797.48
II	Other Income	455.05	229.79	218.30	801.75
III	Total Revenue (I+II)	8,041.33	7,406.96	4,455.13	26,599.23
IV	Expenses :				
	a) Cost of Material Consumed	3,433.30	2,087.48	1,769.88	10,048.25
	b) (Increase)/Decrease in stock in trade and work in progress	(207.68)	567.28	(79.70)	186.12
	c) Employee benefits expenses	746.10	741.45	539.89	2,809.28
	d) Finance Costs	37.01	32.71	60.22	184.01
	e) Depreciation and amortisation expenses	217.81	207.99	209.62	833.40
	f) Other expenses	1,257.89	1,702.08	662.10	4,779.21
	Total Expenses (IV)	5,484.43	5,338.99	3,162.01	18,840.27
V	Profit/(loss) before exceptional items and tax (III-IV)	2,556.90	2,067.97	1,293.12	7,758.95
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	2,556.90	2,067.97	1,293.12	7,758.95
VIII	Tax Expense				
	a) Current Tax	(605.50)	(662.40)	(288.30)	(1,943.00)
	b) MAT Tax	-	-	-	(0.33)
	c) Prior Years	-	(1.82)	-	(143.72)
	d) Deferred Tax	(38.82)	(19.83)	(66.10)	(143.72)
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	1,912.58	1,383.92	938.72	5,671.89
X	Other Comprehensive Income				
	a. Gain/(Loss) on actuarial valuation of post employment benefits	2.10	9.92	(4.64)	(18.82)
	b. Deferred tax on above	(0.53)	(2.49)	1.17	4.74
	c. Other Comprehensive Income (Net of Tax)	1.57	7.43	(3.47)	(14.08)
XI	Total Comprehensive Income	1,914.15	1,391.35	935.25	5,657.81
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90
XXIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	15,136.88
XIV	Earnings Per Share (EPS)				
	a) Basic	₹ 30.96	₹ 22.40	₹ 15.19	₹ 91.81
	b) Diluted	₹ 30.96	₹ 22.40	₹ 15.19	₹ 91.81

Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 30th July, 2021. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrochem Polychem Private Limited.
- Previous period figures have been regrouped/rearranged wherever necessary.

Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 30th July, 2021. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- Previous period figures have been regrouped/rearranged wherever necessary.

Rahul Nechane
 For and On behalf of Board of Directors
 Managing Director